Published in Cancer Weekly, July 17th, 2001
Y. Kondo and colleagues in the Department of Neurosurgery previously reported successful treatment of malignant glioma with 2',5'-oligoadenylate (2-5A) linked to an antisense oligonucleotide against human telomerase RNA (2-5A-anti-hTR), which binds the RNA portion of the telomerase complex, targeting it for RNaseL cleavage. Telomerase activity, which is responsible for maintaining "chromosome integrity in cancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.